KR20240159860A - Vwf 표적화 단일특이적 항체를 사용한 혈액 장애의 치료 방법 - Google Patents

Vwf 표적화 단일특이적 항체를 사용한 혈액 장애의 치료 방법 Download PDF

Info

Publication number
KR20240159860A
KR20240159860A KR1020247030582A KR20247030582A KR20240159860A KR 20240159860 A KR20240159860 A KR 20240159860A KR 1020247030582 A KR1020247030582 A KR 1020247030582A KR 20247030582 A KR20247030582 A KR 20247030582A KR 20240159860 A KR20240159860 A KR 20240159860A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
region
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030582A
Other languages
English (en)
Korean (ko)
Inventor
헨릭 오스터가드
프라풀 에스 간디
요한 에이치 파버
캐서린 레아
베니 소렌슨
Original Assignee
헤맵 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헤맵 에이피에스 filed Critical 헤맵 에이피에스
Publication of KR20240159860A publication Critical patent/KR20240159860A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247030582A 2022-02-15 2023-02-14 Vwf 표적화 단일특이적 항체를 사용한 혈액 장애의 치료 방법 Pending KR20240159860A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268040P 2022-02-15 2022-02-15
US63/268,040 2022-02-15
US202263269000P 2022-03-08 2022-03-08
US63/269,000 2022-03-08
PCT/EP2023/053681 WO2023156409A1 (en) 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Publications (1)

Publication Number Publication Date
KR20240159860A true KR20240159860A (ko) 2024-11-06

Family

ID=85278579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030582A Pending KR20240159860A (ko) 2022-02-15 2023-02-14 Vwf 표적화 단일특이적 항체를 사용한 혈액 장애의 치료 방법

Country Status (8)

Country Link
US (1) US20250154283A1 (https=)
EP (1) EP4479435A1 (https=)
JP (1) JP2025507448A (https=)
KR (1) KR20240159860A (https=)
CN (1) CN119032109A (https=)
AU (1) AU2023221511A1 (https=)
CA (1) CA3244108A1 (https=)
WO (1) WO2023156409A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133583A1 (es) * 2023-08-16 2025-10-15 Hemab Aps Métodos para tratar trastornos de la sangre con anticuerpos monoespecíficos dirigidos a vwf
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides

Also Published As

Publication number Publication date
EP4479435A1 (en) 2024-12-25
JP2025507448A (ja) 2025-03-18
WO2023156409A1 (en) 2023-08-24
US20250154283A1 (en) 2025-05-15
CN119032109A (zh) 2024-11-26
AU2023221511A1 (en) 2024-09-12
CA3244108A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CA2747519C (en) Anti-fxi antibodies and methods of use
US12195549B2 (en) Immunomodulatory antibodies and methods of use thereof
US20190248920A1 (en) Coagulation factor binding proteins and uses thereof
US20250154283A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
JP2021535161A (ja) 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
JP2024116399A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
AU2022210221A1 (en) Immunomodulatory antibodies and uses thereof
US20210214435A1 (en) Antibodies targeting glycoprotein vi
TW202208443A (zh) 蛋白質s抗體、其製造方法及其用途
TW202509085A (zh) 以靶向ｖｗｆ之單專一性抗體治療血液病症的方法
US20240084029A1 (en) Use of immunomodulatory antibodies to treat fibrotic diseases
HK40118720A (zh) 用靶向vwf的单特异性抗体治疗血液病症的方法
JP6445440B2 (ja) 抗プロテインｃ抗体による出血性疾患の治療
WO2019200357A1 (en) Biomarker for cd47 targeting therapeutics and uses therefor
US20250298041A1 (en) Novel assay for the platelet binding activity of the von willebrand factor
CN117062835A (zh) 免疫调节性抗体及其用途
CN118414168A (zh) 因子xi a2结构域结合抗体和其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application